Related Experiment Video
Updated: Jun 12, 2026
13:38
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Primary systemic chemotherapy for inflammatory breast cancer
Sarah Sinclair1, Sandra M Swain
1Department of Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Cancer
|May 27, 2010
Summary
Multimodality therapy, including chemotherapy, improves survival for inflammatory breast cancer (IBC). Achieving a pathologic complete response is significant for better outcomes in this aggressive cancer.
Area of Science:
- Oncology
- Breast Cancer Research
- Cancer Therapy
Background:
- Inflammatory breast cancer (IBC) is an aggressive form of breast cancer.
- Multimodality therapy, including neoadjuvant chemotherapy, surgery, radiotherapy, and hormonal therapy, has improved survival rates for IBC patients.
- Pathologic complete response (pCR) to neoadjuvant chemotherapy is associated with improved outcomes in locally advanced breast cancer and IBC.
Purpose of the Study:
- To review the current landscape of multimodality therapy for inflammatory breast cancer.
- To highlight the prognostic significance of achieving a pathologic complete response to neoadjuvant chemotherapy.
- To identify potential therapeutic targets, such as angiogenesis, for improved IBC treatment.
Main Methods:
- Review of existing literature on multimodality therapy for inflammatory breast cancer.
- Analysis of the prognostic value of pathologic complete response.
- Discussion of emerging therapeutic targets and future research directions.
Main Results:
- Multimodality therapy has led to improved survival for patients with inflammatory breast cancer.
- A pathologic complete response to neoadjuvant chemotherapy is a significant predictor of better outcomes.
- Vascular endothelial growth factor (VEGF) is highly expressed in IBC, suggesting angiogenesis as a viable therapeutic target.
Conclusions:
- Multimodality therapy has enhanced survival for IBC patients.
- Achieving a pathologic complete response is crucial for improved prognosis.
- Targeting angiogenesis and further understanding IBC biology are essential for developing novel therapies.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...